Gastrointestinal release behaviour of modified-release drug products: Dynamic dissolution testing of mesalazine formulations

International Journal of Pharmaceutics

Volumn 484, Issue 1-2, 2015, Pages 103-108

  Goyanes, Alvaro ^a   Hatton, Grace B ^a   Merchant, Hamid A ^a,b   Basit, Abdul W ^a,c  

^a UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY OF HUDDERSFIELD   (United Kingdom)

^c London Bioscience Innovation Centre   (United Kingdom)

Author keywords

5 Aminosalicylic acid; 5 ASA; Biorelevant dissolution; Colonic delivery; Enteric coatings; Physiological bicarbonate buffers

Indexed keywords

BUFFER; MESALAZINE; DELAYED RELEASE FORMULATION;

ARTICLE; DRUG DOSAGE FORM; DRUG FORMULATION; DRUG RELEASE; DRUG SOLUBILITY; GAMMA SCINTIGRAPHY; GASTROINTESTINAL TRACT; HUMAN; IN VITRO STUDY; INFLAMMATORY BOWEL DISEASE; IONIC STRENGTH; MATERIAL COATING; PH; PRIORITY JOURNAL; CHEMISTRY; DELAYED RELEASE FORMULATION; DRUG EFFECTS; MEDICINAL CHEMISTRY; METABOLISM; PHARMACOKINETICS; SOLUBILITY;

CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; DRUG LIBERATION; GASTROINTESTINAL TRACT; HUMANS; MESALAMINE; SOLUBILITY;

EID: 84923637404     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2015.02.051     Document Type: Article

References (39)

1. R. D'Inca, M. Paccagnella, R. Cardin, S. Pathak, V. Baldo, M.C. Giron, and G.C. Sturniolo 5-ASA colonic mucosal concentrations resulting from different pharmaceutical formulations in ulcerative colitis World J. Gastroenterol. 19 2013 5665 5670
2. S.S. Davis, J.G. Hardy, and J.W. Fara Transit of pharmaceutical dosage forms through the small intestine Gut 27 1986 886 892
3. eMC-Asacol, 2014. Summaries of product characteristics: Asacol 800 mg MR tablets. https://www.medicines.org.uk/emc/medicine/20478 (accessed 12.10.14.).
4. eMC-Mezavant, 2014. Summaries of product characteristics: Mezavant XL 1200, gastro-resistant, prolonged release tablets. https://www.medicines.org.uk/emc/medicine/20347 (accessed 12.10.14.).
5. eMC-Salofalk, 2014. Summaries of product characteristics: Salofalk 500 mg gastro-resistant prolonged-release granules. https://www.medicines.org.uk/emc/medicine/16909 (accessed 12.10.14.).
6. D.F. Evans, G. Pye, R. Bramley, A.G. Clark, T.J. Dyson, and J.D. Hardcastle Measurement of gastrointestinal pH profiles in normal ambulant human subjects Gut 29 1988 1035 1041
7. H.M. Fadda, H.A. Merchant, B.T. Arafat, and A.W. Basit Physiological bicarbonate buffers: stabilisation and use as dissolution media for modified release systems Int. J. Pharm. 382 2009 56 60
8. H.M. Fadda, T. Sousa, A.S. Carlsson, B. Abrahamsson, J.G. Williams, D. Kumar, and A.W. Basit Drug solubility in luminal fluids from different regions of the small and large intestine of humans Mol. Pharm. 7 2010 1527 1532
9. J. Fallingborg, L.A. Christensen, B.A. Jacobsen, and S.N. Rasmussen Very low intraluminal colonic pH in patients with active ulcerative colitis Dig. Dis. Sci. 38 1993 1989 1993
10. B.G. Feagan, N. Chande, and J.K. MacDonald Are there any differences in the efficacy and safety of different formulations of oral 5-ASA used for induction and maintenance of remission in ulcerative colitis? Evidence from cochrane reviews Inflamm. Bowel Dis. 19 2013 2031 2040
11. A.C. Freire, A.W. Basit, R. Choudhary, C.W. Piong, and H.A. Merchant Does sex matter? The influence of gender on gastrointestinal physiology and drug delivery Int. J. Pharm. 415 2011 15 28
12. G. Garbacz, B. Kolodziej, M. Koziolek, W. Weitschies, and S. Klein An automated system for monitoring and regulating the pH of bicarbonate buffers AAPS PharmSciTech 14 2013 517 522
13. A. Goyanes, A.B. Buanz, G.B. Hatton, S. Gaisford, and A.W. Basit 3D printing of modified-release aminosalicylate (4-ASA and 5-ASA) tablets Eur. J. Pharm. Biopharm. 89 2015 157 162
14. A. Goyanes, G.B. Hatton, and A.W. Basit A dynamic in vitro model to evaluate the intestinal release behaviour of modified-release corticosteroid products J. Drug Deliv. Sci. Tech. 25 2015 36 42
15. A.I. Harianawala, R.H. Bogner, and M. Bradley Measurement of pH near dissolving enteric coatings Int. J. Pharm. 247 2002 139 146
16. V.C. Ibekwe, H.M. Fadda, E.L. McConnell, M.K. Khela, D.F. Evans, and A.W. Basit Interplay between intestinal pH, transit time and feed status on the in vivo performance of pH responsive ileo-colonic release systems Pharm. Res. 25 2008 1828 1835
17. V.C. Ibekwe, M.K. Khela, D.F. Evans, and A.W. Basit A new concept in colonic drug targeting: a combined pH-responsive and bacterially-triggered drug delivery technology Aliment. Pharmacol. Ther. 28 2008 911 916
18. S. Klein, J. Stein, and J. Dressman Site-specific delivery of anti-inflammatory drugs in the gastrointestinal tract: an in-vitro release model J. Pharm. Pharmacol. 57 2005 709 719
19. 2, bicarbonate in vivo buffer system J. Pharm. Sci. 103 2014 3473 3490
20. G.R. Lichtenstein, and M.A. Kamm Review article: 5-aminosalicylate formulations for the treatment of ulcerative colitis - methods of comparing release rates and delivery of 5-aminosalicylate to the colonic mucosa Aliment. Pharmacol. Ther. 28 2008 663 673
21. F. Liu, R. Lizio, C. Meier, H.U. Petereit, P. Blakey, and A.W. Basit A novel concept in enteric coating: a double-coating system providing rapid drug release in the proximal small intestine J. Control. Release 133 2009 119 124
22. F. Liu, H.A. Merchant, R.P. Kulkarni, M. Alkademi, and A.W. Basit Evolution of a physiological pH 6.8 bicarbonate buffer system: application to the dissolution testing of enteric coated products Eur. J. Pharm. Biopharm. 78 2011 151 157
23. M. McAllister Dynamic dissolution: a step closer to predictive dissolution testing? M. Pharm. 7 2010 1374 1387
24. E.L. McConnell, H.M. Fadda, and A.W. Basit Gut instincts: explorations in intestinal physiology and drug delivery Int. J. Pharm. 364 2008 213 226
25. E.L. McConnell, M.D. Short, and A.W. Basit An in vivo comparison of intestinal pH and bacteria as physiological trigger mechanisms for colonic targeting in man J. Control. Release 130 2008 154 160
26. E.L. McConnell, F. Liu, and A.W. Basit Colonic treatments and targets: issues and opportunities J. Drug Target. 17 2009 335 363
27. Merchant, H.A.; Frost, J.; Basit, A.W.; 2012. Apparatus and method for testing medicaments. PCT/GB2013/051145.
28. H.A. Merchant, A. Goyanes, N. Parashar, and A.W. Basit Predicting the gastrointestinal behaviour of modified-release products: utility of a novel dynamic dissolution test apparatus involving the use of bicarbonate buffers Int. J. Pharm. 475 2014 585 591
29. B. Narasimhan, and N.A. Peppas The physics of polymer dissolution: modeling approaches and experimental behaviour A. Andrady, Polymer Analysis, Polymer Physics 1997 Springer-Verlag New York 157 207
30. D.A. Nguyen, and H.S. Fogler Facilitated diffusion in the dissolution of carboxylic polymers AIChE J. 51 2005 415 425
31. S.G. Nugent, D. Kumar, D.S. Rampton, E. Yazaki, and D.F. Evans Gut pH and transit time in ulcerative colitis appear sufficient for complete dissolution of pH-dependent mesalazine-containing capsules Gut 46 2000 A9
32. S. Nugent, D. Kumar, D. Rampton, and D. Evans Intestinal luminal pH in inflammatory bowel disease: possible determinants and implications for therapy with aminosalicylates and other drugs Gut 48 2001 571 577
33. S.S. Ozturk, B.O. Palsson, B. Donohoe, and J.B. Dressman Kinetics of release from enteric-coated tablets Pharm. Res. 5 1988 550 565
34. R.C.A. Schellekens, F.E. Stuurman, F.H.J. van der Weert, J.G.W. Kosterink, and H.W. Frijlink A novel dissolution method relevant to intestinal release behaviour and its application in the evaluation of modified release mesalazine products Eur. J. Pharm. Sci. 30 2007 15 20
35. F.J. Varum, G.B. Hatton, and A.W. Basit Food: physiology and drug delivery Int. J. Pharm. 457 2013 446 460
36. F.J. Varum, G.B. Hatton, A.C. Freire, and A.W. Basit A novel coating concept for ileo-colonic drug targeting: proof of concept in humans using scintigraphy Eur. J. Pharm. Biopharm. 84 2013 573 577
37. F.J. Varum, H.A. Merchant, A. Goyanes, P. Assi, V. Zboranova, and A.W. Basit Accelerating the dissolution of enteric coatings in the upper small intestine: evolution of a novel pH 5.6 bicarbonate buffer system to assess drug release Int. J. Pharm. 468 2014 172 177
38. H. Wray, R. Joseph, M. Palmen, and D. Pierce Combined pharmacokinetic and scintigraphic analyses for the comparison of 5-ASA release profiles from MMX™ mesalamine and another delayed-release mesalamine formulation: P-0030 Inflamm. Bowel Dis. 14 2008 S19 S20
39. N. Yoshimura, T. Tadami, T. Kawaguchi, M. Sako, A. Saniabadi, and M. Takazoe Sa1112 long-term efficacy of a pH-dependent release mesalamine formulation, Asacol in patients with ulcerative colitis who showed inadequate response to a time-dependent release mesalamine formulation, Pentasa: a prospective study Gastroenterology 144 2013 S-205